GFAP Antikörper

Produktnummer ABIN335357

Der Maus Monoklonal Anti-GFAP-Antikörper wurde für WB, IHC, IHC (p) und IHC (fro) validiert. Er ist geeignet, GFAP in Proben von Human zu detektieren. Es ist 1 Publikation verfügbar.

Kurzübersicht für GFAP Antikörper (ABIN335357)

Target: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser GFAP Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Klon: 6F2

Produktdetails anti-GFAP Antikörper

Spezifität: Human.

Aufreinigung: Purified

Immunogen: 6F2 is a mouse monoclonal IgG1 antibody derived by fusion of mouse myeloma cells with spleen cells from a mouse immunized with glial fibrillary acidic protein from human brain.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: 6F2 reacts exclusively with glial fibrillary acidic protein which is present in astrocytes in the central nervous system and Schwann cells. 6F2 is suitable for immunoblotting and immunohistochemistry on frozen and paraffin-embedded tissues. Optimal antibody dilution should be determined by titration, recommended range is 1:25 - 1:200 for immunohistochemistry with avidin-biotinylated horseradish peroxidase complex (ABC) as detection reagent, and 1:100 - 1:1000 for immunoblotting applications.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Referenzen für anti-GFAP Antikörper (ABIN335357)

Van Muijen, Ruiter, Warnaar: "Coexpression of intermediate filament polypeptides in human fetal and adult tissues." in: Laboratory investigation; a journal of technical methods and pathology, Vol. 57, Issue 4, pp. 359-69, (1987) (PubMed).

Details zu GFAP

Target: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Andere Bezeichnung: Glial fibrillary acidic protein / GFAP

Hintergrund: GFAP (55 kD) is selectively located in astrocytes and represents the major constituent of astrocytic intermediate filaments. GFAP expression levels are highly variable during development of the central nervous system. In adults, GFAP levels increase as a result of the proliferation of astrocytes that occurs in a response to a variety of physical, chemical and etiological insults, including Alzheimer€™s disease, epilepsy and multiple sclerosis. In the peripheral nervous system GFAP is expressed by Schwann cells. Upon differentiation, myelin forming Schwann cells down-regulate GFAP, whereas in non-myelin forming Schwann cells GFAP persists into adulthood.